Critical Outcome Technologies Inc. (COTI)

Critical Outcome Technologies Inc. (COTI)

May 24, 2012 09:00 ET

Critical Outcome Technologies Inc. Selected to Present CHEMSAS® as a Drug Discovery Platform

LONDON, ONTARIO--(Marketwire - May 24, 2012) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that Dr. Wayne Danter, President and CEO, has been invited to deliver a presentation on May 25, 2012 at the Salford Analytics and Data Mining Conference in San Diego, CA. The presentation is entitled CHEMSAS®: A Machine Learning Platform for Drug Discovery.

The presentation provides an overview of CHEMSAS®, COTI's proprietary artificial intelligence platform technology, with specific reference to COTI's Acute Myelogenous Leukemia (AML) program as a practical example of COTI's ability to discover novel drug candidates using CHEMSAS®. "This upcoming presentation affords us an excellent opportunity to highlight the potential of CHEMSAS® to a targeted audience of key influencers in the data mining, bioinformatics, pharmaceutical and biotechnology industries," said Dr. Danter.

CHEMSAS® utilizes a series of computer simulations to discover, optimize and select novel targeted compounds for rapid patenting and preclinical development. CHEMSAS® is built on a series of proprietary algorithms that are applied to complex 3D molecular structures of small molecules to produce unique 2D data patterns composed of more than 300 proprietary descriptors. These unique molecular data patterns are then used to develop hybrid predictive models relating molecular structure to specific biological properties that previously required expensive and time consuming in vitro and/or in vivo tests. Computer optimized structures are then edited and further optimized and the final potential lead candidates are selected based on an optimal profile of probable physical, chemical, biological, efficacy and ADMET properties.

COTI's AML program has the potential to produce multiple drug candidates with differing activity profiles that can be used to treat acute leukemias with different gene mutation profiles. These candidates have been granted composition of matter patents for the underlying molecular scaffolds in the United States, Canada and Europe and six compounds are synthesized and are currently undergoing in vitro confirmatory testing.

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling these new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information